Navigation Links
Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
Date:1/18/2008

SOMERSET, N.J., Jan. 18 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it has entered into a purchase and supply agreement with Scientific Protein Laboratories LLC (SPL) for the commercial production of ONCONASE(R) (ranpirnase). ONCONASE, the company's lead drug candidate, is currently being evaluated as a treatment for unresectable malignant mesothelioma (UMM) in a confirmatory Phase IIIb clinical trial.

"SPL has been involved in the production of ONCONASE from the very first batches," said Kuslima Shogen, chief executive officer of Alfacell. "We have been pleased with the superb performance of the extremely well qualified team at SPL for many years and are confident that the commercial production of ONCONASE is in the right hands. This agreement is another step forward for Alfacell as we plan for the commercialization of ONCONASE."

"We have been very enthusiastic about the Alfacell project from the very beginning," said David Strunce, president and chief executive officer of SPL. "We are impressed by the way that Alfacell has successfully guided their novel product through the development phases, and we are pleased to have the opportunity to continue the collaboration with the Alfacell team into the commercial stage."

About Scientific Protein Labs LLC

For over three decades, Scientific Protein Laboratories (SPL) has been a leading global supplier of high quality active pharmaceutical ingredients (APIs) from natural sources. The company specializes in cGMP biopharmaceutical manufacturing and is among the largest commercial suppliers of Heparin Sodium USP, Pancreatin USP and Pancrelipase USP in serving the pharmaceutical, veterinary and food industries globally. Beyond supply
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
2. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
3. Alfacell to Present at BIO InvestorForum 2007
4. Peptimmune Announces First Close of Series D Private Financing
5. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
6. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
7. Vasogen Announces 2007 Year-End Results
8. RSB Spine, LLC Announces First Implantation of the InterPlate(TM) L for the Lumbar Spine
9. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
10. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
11. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... York (PRWEB) August 29, 2014 According to ... Orthobiologics Market” the global orthobiologics market was valued at USD ... market worth USD 5,519.9million in 2019at a CAGR of 5.9% ... aged 50 years and above is afflicted by bone and ... by the year 2020. This has and will continue to ...
(Date:8/29/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the six months ended June 30, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... , Announced top-line results related to the eight ... enrolled in the Phase 2 iDEAL Study evaluating ...
(Date:8/29/2014)... Three Lawrence Livermore researchers have ... Production R&D Award for their research in ... sunlight. , Shared with collaborators from the National ... Nevada, Las Vegas (UNLV), the award recognizes the ... solar-hydrogen production and corrosion processes. , These models ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... BIG SP, Company or Biosensors), today announced that ... for its,BioMatrix(R) drug-eluting stent system, enabling commercialization of ... in Asia and Latin America,that recognize the CE ... the Company, consists of a unique drug-eluting,stent that ...
... Calif., Jan. 17 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... meetings including yearend business review, planning for ... in,Xiaotangshan, Beijing on January 11, 2008., ... from Kiwa,s corporate,headquarters in Beijing, and department ...
... formed Advisory Board to advise on cancer screening methods ... mitochondrial DNA-based disease ... (OTC,Bulletin Board: TBIO) today announced that it has formed ... latest developments and,scientific opportunities in cancer detection screening and ...
Cached Biology Technology:Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 2Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 3Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 4Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 2Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 3Transgenomic, Inc. Forms Scientific Advisory Board 2Transgenomic, Inc. Forms Scientific Advisory Board 3
(Date:8/28/2014)... method for delivering compounds that could positively ... AIDS may be possible, thanks to researchers ... A semi-soft vaginal suppository made from the ... the antiviral drug Tenofovir provides a woman-initiated, ... spread of sexually transmitted infections during unprotected ...
(Date:8/28/2014)... for measuring and imaging how quickly blood flows in ... how drug abuse affects the brain, which may aid ... to better treatment options for recovering drug addicts. The ... Stony Brook University in New York, USA and the ... The Optical Society,s (OSA) open-access journal Biomedical ...
(Date:8/28/2014)... German . Cars, ... help of sophisticated assembly lines. Mobile assembly carriers, on to ... these assembly lines. In the case of a car body, ... in a precise spatial and chronological sequence, resulting in a ... creation of such an assembly line at molecular level has ...
Breaking Biology News(10 mins):Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Nanoscale assembly line 2Nanoscale assembly line 3
... has discovered that aggressive melanoma cells secrete Nodal, ... formation. , An article describing this research ... of the journal Nature Medicine. The researchers identified the ... injecting aggressive melanoma cells into developing zebrafish embryos, ...
... known more for conflict than conservation, a joint effort ... Society (WCS) and funded by the United States Agency ... the region's unique wildlife and develop the country's first ... is an important and exciting moment for Afghanistan, which ...
... Methylphenidate (Ritalin) elevates norepinephrine levels in the brains ... nerve signal transmissions in the sensory pathways to ... a Philadelphia research team has found. , Their ... how a stimulant aids people with attention deficit ...
Cached Biology News:Malignant melanoma cells secrete protein required for embryo formation 2Afghanistan to protect wildlife and wild lands 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 3